Phase 1b study of safety, tolerability and efficacy of R1507, a monoclonal antibody to IGF-1R in combination with multiple standard oncology regimens in patients with advanced solid malignancies
Daruka Mahadevan, Gregory Ryan Sutton, Rafael Arteta-Bulos, Chris J. Bowden, Paul J.E. Miller, Rachel Elizabeth Swart, Mark S. Walker, Paul Haluska, Pamela N. Munster, John Marshall, Omid Hamid, Razelle Kurzrock
Dive into the research topics of 'Phase 1b study of safety, tolerability and efficacy of R1507, a monoclonal antibody to IGF-1R in combination with multiple standard oncology regimens in patients with advanced solid malignancies'. Together they form a unique fingerprint.